PHVS: Deucrictibant's strong efficacy and safety data support its launch as a leading oral HAE therapy
Deucrictibant demonstrated high efficacy and a favorable safety profile in severe HAE patients, positioning it as a differentiated oral therapy for both on-demand and prophylactic use. Launch preparations are advanced, with strong patient interest and a robust pipeline supporting future growth.Base…